Thrombosis with associated inflammation (thromboinflammation) occurs commonly in a
broad range of human disorders. It is well recognized clinically in the context of superficial …

Aside from their role in hemostasis, coagulant and fibrinolytic proteases are important
mediators of inflammation in diseases such as asthma, atherosclerosis, rheumatoid arthritis …

Anti-platelet drugs reduce arterial thrombosis after plaque rupture and erosion, prevent stent
thrombosis and are used to prevent and treat myocardial infarction and ischaemic stroke …

Protease-activated receptors (PARs) are a ubiquitously expressed class of G-protein-
coupled receptors (GPCRs) that enable cells to respond to proteases in the extracellular …

Protease‐activated receptors are a family of four GPCRs (PAR1–PAR4) with a number of
unique attributes. Nearly two and a half decades after the discovery of the first PAR, an …

Cardiovascular diseases (CVDs) are currently among the leading causes of death
worldwide. Platelet aggregation is a key cellular component of arterial thrombi and major …

Seamlessly bridging the hard and the soft, a strategy to fabricate hierarchically porous
NiTi/hydrogels nanocomposites is reported. The nanocomposite surface can hold high …

Essentials• The platelet thrombin receptor, PAR4, is an emerging anti‐thrombotic drug
target.• We examined the anti‐platelet & anti‐thrombotic effects of PAR4 inhibition in human …

Fibrosis causes irreversible damage to lung structure and function in restrictive lung
diseases such as idiopathic pulmonary fibrosis (IPF). Extravascular coagulation involving …

Protease activated receptors (PARs) are G-protein coupled receptors (GPCRs) that have a
unique activation mechanism. Unlike other GPCRs that can be activated by free ligands …